Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer

Authors

  • Inês Barreto Pulmonology Department, Centro Hospitalar Universitário Lisboa Norte, Portugal https://orcid.org/0000-0002-1127-4811
  • Sara Figueiredo Oncology-Medical Department, AstraZeneca Portugal
  • Fernanda S. Tonin Post-doctoral researcher, Health Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Portugal
  • Ana Sofia Vilariça Pulmonology Department, Centro Hospitalar Universitário Lisboa Norte, Portugal
  • Direndra Hasmucrai Pulmonology Department, Centro Hospitalar Universitário Lisboa Norte, Portugal
  • Paula Alves Pulmonology Department, Centro Hospitalar Universitário Lisboa Norte, Portugal

DOI:

https://doi.org/10.48729/pjctvs.381

Keywords:

non-small-cell lung cancer, EGFR mutation, tyrosine kinase inhibitors, real-world data

Downloads

Download data is not yet available.

References

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (updated). European Society for Medical Oncology (ESMO) available at https://wwwesmoorg/content/download/347819/6934778/1/ESMO-CPG-mNSCLC-15SEPT-2020pdf 2020.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4(9):1046-61.

Li L, Huang Q, Sun J, Yan F, Wei W, Li Z, et al. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta Oncol 2022;61(11):1347-53.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378(2):113-25.

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020;383(18):1711-23.

Frampton JE. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. Target Oncol 2022;17(3):369-76.

Mu Y, Hao X, Xing P, Hu X, Wang Y, Li T, et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. J Cancer Res Clin Oncol 2020;146(9):2427-33.

Downloads

Published

11-10-2023

How to Cite

1.
Barreto I, Figueiredo S, Tonin FS, Vilariça AS, Hasmucrai D, Alves P. Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer. Rev Port Cir Cardiotorac Vasc [Internet]. 2023 Oct. 11 [cited 2024 Nov. 21];30(3):9-11. Available from: https://pjctvs.com/index.php/journal/article/view/381

Issue

Vol. 30 No. 3 (2023): Jul-Sep

Section

Letter to the Editor

Categories

License

Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgery

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.